Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
05/2012
05/17/2012US20120122768 Alginate oligomers for use in overcoming multidrug resistance in bacteria
05/17/2012US20120122766 Novel Polypeptide Having Angiogenesis-Inducing Activity And Antibacterial Activity, And Use Thereof For Medical Purposes
05/17/2012US20120122762 186 Human Secreted Proteins
05/17/2012US20120122186 Novel bacteriophage strains for the treatment of bacterial infections, especially drug resistant strains of the genus enterococcus
05/17/2012US20120122185 Chimeric viruses presenting non-native surface proteins and uses thereof
05/17/2012US20120121744 Pharmaceutical composition for inhibiting infection and replication of influenza a and b virus, and the manufacture thereof
05/17/2012US20120121741 Water soluble defructosylated pea extract, and use thereof as a prebiotic agent
05/17/2012US20120121730 Pharmaceutical and nutraceutical compositions for treating respiratory disease and associated phlegm
05/17/2012US20120121724 Film comprising therapeutic agents
05/17/2012US20120121721 Skin care products and compositions
05/17/2012US20120121717 DRUG-LOADED POLYSACCHARIDE-COATED GOLDMAG PARTICLES (DPGPs) AND ITS SYNTHESIS METHOD
05/17/2012US20120121715 DNA Vaccine Comprising IL-6-Encoding DNA Construct and Applications Thereof
05/17/2012US20120121714 Compositions with antigens adsorbed to calcium phosphate
05/17/2012US20120121711 Microsphere drug carrier, preparation method, composition and use thereof
05/17/2012US20120121710 Mucosal Immunization
05/17/2012US20120121702 Controlled Release Azithromycin Solid Dosage Forms
05/17/2012US20120121701 Pharmaceutical composition of peptide drug and enzyme-inhibition compounds
05/17/2012US20120121700 Pharmaceutical formulations comprising valganciclovir
05/17/2012US20120121698 Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
05/17/2012US20120121695 Acoustically sensitive drug delivery particles comprising non-lamellar forming phosphatidylethanolamine
05/17/2012US20120121690 Method to enhance an immune response of nucleic acid vaccination
05/17/2012US20120121689 Small interfering rna delivery
05/17/2012US20120121679 Viricidal and microbicidal compositions and uses thereof
05/17/2012US20120121674 Nonwoven fabric products with enhanced transfer properties
05/17/2012US20120121668 Compositions for oral adminstration of active principles requiring masking of taste
05/17/2012US20120121665 Implantable or insertable medical device resistant to microbial growth and biofilm formation
05/17/2012US20120121664 Gastric Acid Secretion Inhibiting Composition
05/17/2012US20120121661 Devices with multiple surface functionality
05/17/2012US20120121648 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
05/17/2012US20120121647 Influenza vaccine, composition, and methods of use
05/17/2012US20120121646 Vaccine
05/17/2012US20120121645 Supralingual vaccines and applicators
05/17/2012US20120121644 Sticky soft gel for treating poultry
05/17/2012US20120121639 Proteins with repetitive bacterial-ig-like (big) domains present in leptospira species
05/17/2012US20120121638 Polypeptide Derived From Enterococcus And Its Use For Vaccination
05/17/2012US20120121636 Tat-Based Vaccine Compositions and Methods of Making and Using Same
05/17/2012US20120121635 Expression in plants of HIV-related proteins
05/17/2012US20120121634 Soluble pd-1 variants, fusion constructs, and uses thereof
05/17/2012US20120121633 Hiv cd4 binding site based covalent immunogen compositions
05/17/2012US20120121632 TAT Protein for preventing or treating AIDS
05/17/2012US20120121631 Polyvalent vaccine
05/17/2012US20120121629 New human rotavirus vaccine strains and diagnostics
05/17/2012US20120121628 Lipidated polyepitope vaccines
05/17/2012US20120121624 Hepatitis c virus ns3 protease inhibitors
05/17/2012US20120121623 Novel antipathogenic peptides
05/17/2012US20120121622 Biodegradable immunomodulatory formulations and methods for use thereof
05/17/2012US20120121621 Synergistic prebiotic compositions
05/17/2012US20120121617 Promoters for recombinant viral expression
05/17/2012US20120121616 Immune balance-regulating agent
05/17/2012US20120121607 Antibodies to clostridium difficile toxins
05/17/2012US20120121603 Compositions And Methods For The Therapy And Diagnosis Of Influenza
05/17/2012US20120121602 Novel proteins
05/17/2012US20120121601 Mammalian receptor proteins; related reagents and methods
05/17/2012US20120121597 Fusion proteins for hiv therapy
05/17/2012US20120121593 Method for determining predisposition to pulmonary infection
05/17/2012US20120121592 Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells
05/17/2012US20120121588 Modulation of pilr receptors to treat sepsis
05/17/2012US20120121578 Methods of using immunoglobulin aggregates
05/17/2012US20120121574 Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore
05/17/2012US20120121572 New medicines for topic use based on sulfated hyaluronic acid as activating or inhibiting agent of the cytokine activity
05/17/2012US20120121569 Methods of treating infections originating from viruses in the herpesviridae family
05/17/2012US20120121562 Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients
05/17/2012US20120121543 Anti-microbial agent from paenibacillus sp. and methods and uses thereof
05/17/2012US20120121541 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
05/17/2012US20120121538 Combined measles-malaria vaccine
05/17/2012US20120121537 Methods and Compositions for Inhibiting Hepatitis C Virus Replication
05/17/2012US20120121522 Metabolized conditioned growth medium and methods of use
05/17/2012US20120121461 Hand sanitizer
05/17/2012CA2742532A1 Treatment or prevention of fungal infections with pdk1 inhibitors
05/16/2012EP2452944A1 Diphenyl sulfide derivatives and medicines containing same as active ingredient
05/16/2012EP2452935A2 Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
05/16/2012EP2452693A2 Vaccines and methods to treat canine influenza
05/16/2012EP2452684A2 Micelles
05/16/2012EP2452682A1 Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
05/16/2012EP2452680A1 Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement
05/16/2012EP2452676A1 Hydrogel comprising deuterium oxide for treating herpesvirus-based inflammations of the skin
05/16/2012EP2451822A1 New antiviral compounds useful for the treatment or the prevention of epidemic keratoconjonctivitis
05/16/2012EP2451815A1 INDUCTION OF alpha-HELIX CONFORMATIONS IN PROTEINS AND PEPTIDES
05/16/2012EP2451800A1 1-(6 members azo-heterocyclic)-pyrrolin-2-one compounds as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use
05/16/2012EP2451453A1 Substituted pyrrolidinone as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use
05/16/2012EP2268648B1 Crystalline (6R,7R)-7-{2-(5-Amino-[1,2,4]thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1'-tert- butoxycarbonyl-2-oxo-[1,3]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use
05/16/2012EP2086940B1 Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
05/16/2012EP1480993B2 Desaturase genes, enzymes encoded thereby, and uses thereof
05/16/2012DE102010051430A1 The agent useful for treating an infection caused by a virus from the group including human papillomavirus, comprises a neuraminidase inhibitor as an essential component
05/16/2012DE102007037579B4 Neue Benzimidazol-2-yl-alkylamine und ihre Anwendung als mikrobizide Wirkstoffe New benzimidazol-2-yl-alkylamines and their application as microbicidal agents
05/16/2012CN102459651A Method of determining response to treatment with immunomodulatory composition
05/16/2012CN102459343A Anti cxcr4 antibodies for treatment of hiv
05/16/2012CN102459321A 酪蛋白来源的蛋白酶抑制肽 Casein-derived protease inhibitory peptide
05/16/2012CN102459299A N- [ (2 ' r) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-p-phenyl-5 ' -uridylyl] -l-alanine 1-methylethyl ester and process for its production
05/16/2012CN102459296A 具有抗微生物活性的酮内酯类化合物 Within one has antimicrobial activity Esters
05/16/2012CN102459281A 丙型肝炎病毒抑制剂 Hepatitis C virus inhibitors
05/16/2012CN102459280A 作为病毒复制抑制剂的噻吩并[2,3-b]吡啶衍生物 As inhibitors of viral replication thieno [2,3-b] pyridine derivatives
05/16/2012CN102459253A Oxazole substituted indazoles as pi3-kinase inhibitors
05/16/2012CN102459250A 丙型肝炎病毒抑制剂 Hepatitis C virus inhibitors
05/16/2012CN102459245A Thioxanthene derivatives for the treatment of infectious diseases
05/16/2012CN102459224A 5-alkynyl-pyridines
05/16/2012CN102459201A 杀真菌的1，2，4-三唑衍生物 Fungicidal 1,2,4-triazole derivatives
05/16/2012CN102459183A Inhibitors of human immunodeficiency virus replication
05/16/2012CN102458470A Alpha thymosin peptides as vaccine enhancers
05/16/2012CN102458463A Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
1 ... 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 ... 1798